KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short-term Investments: 2012-2025

Historic Short-term Investments for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $129.8 million.

  • Supernus Pharmaceuticals' Short-term Investments fell 65.07% to $129.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.8 million, marking a year-over-year decrease of 65.07%. This contributed to the annual value of $384.3 million for FY2024, which is 113.70% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Short-term Investments stood at $129.8 million for Q3 2025, which was down 65.65% from $377.9 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Short-term Investments' 5-year high stood at $384.3 million during Q4 2024, with a 5-year trough of $105.2 million in Q3 2023.
  • Moreover, its 3-year median value for Short-term Investments was $234.3 million (2024), whereas its average is $247.5 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first soared by 253.16% in 2024, then crashed by 65.07% in 2025.
  • Supernus Pharmaceuticals' Short-term Investments (MRQ) stood at $136.2 million in 2021, then soared by 170.26% to $368.2 million in 2022, then plummeted by 51.16% to $179.8 million in 2023, then soared by 113.70% to $384.3 million in 2024, then tumbled by 66.23% to $129.8 million in 2025.
  • Its last three reported values are $129.8 million in Q3 2025, $377.9 million for Q2 2025, and $347.7 million during Q1 2025.